retatrutide co to jest Diagram showing the mechanism of action of Retatrutide — AJ Research Labs

Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States

Benefits You should think about the effect of these possible side reactions

The brain response GLP-1 crosses the blood-brain barrier through passive diffusion and receptor-mediated transcytosis

Seek emergency care immediately for signs of allergic reaction, severe abdominal pain with fever, or inability to keep fluids down for more than 6 hours